Michael Trautmann, MD

Michael Trautmann has over 25 years of biopharmaceutical industry experience and has been a consultant since 2012. He studied medicine at the Universities of Goettingen and Marburg, Germany and Geneva, Switzerland. His PostDoc at the Institute of Clinical Biochemistry and Experimental Diabetology at the University of Geneva (under Claes Wollheim and Albert Renold) was supported by the German National Research Fund (DFG). His clinical training in Internal Medicine and Gastroenterology in the Department of Internal Medicine, University Hospital Marburg, Germany (Head: Rudolph Arnold) focused on Diabetes and the Endocrine Gut. 1993-2012 he worked at Eli Lilly in Germany and mostly in global functions in Indianapolis, IN, USA. He was involved in clinical development programs in all stages from preclinical to Phase IV. His involvement included insulin developments (including Lispro insulin), obesity drugs (including leptin), and GLP-1 receptor agonists (including exenatide in the Lilly-Amylin alliance) resulting in 4 global drug approvals and numerous publications. Proven strengths include IND/NDA compilation and management (including EU submissions and Japan), protocol design and development, study report generation. Excellent interpersonal and communication skills with the ability to lead teams to achieve objectives successfully.